1. World Cancer Research Fund (WCRF): Breast cancer statistics. Breast cancer is the most common cancer in women worldwide. WCRF, London, 2018. https://www.wcrf.org/dietandcancer/cancer-trends/breast-cancer-statistics.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71: 209-249, 2021. PMID: 33538338. DOI: 10.3322/caac.21660
3. 全国がんセンター協議会ホームページ:全がん協生存率調査https://www.zengankyo.ncc.go.jp/etc/index.html
4. 日本乳癌学会編「科学的根拠に基づく乳がん診療ガイドライン」(1)治療編 2013年版
5. Colleoni M, Bagnardi V, Rotmensz N, Dellapasqua S, Viale G, Pruneri G, Veronesi P, Torrisi R, Luini A, Intra M, Galimberti V, Montagna E, Goldhirsch A. A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer. Ann Oncol 20: 1178-84, 2009. PMID: 19218304 DOI: 10.1093/annonc/mdn747
6. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkilä P, Heikkinen T, Nevanlinna H, Akslen LA, Bégin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, García-Closas M, Caldas C, Pharoah PD, Huntsman D. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 7: e1000279, 2010. PMID: 20520800 PMCID: PMC2876119 DOI: 10.1371/journal.pmed.1000279
7. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE and Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874, 2001. PMID: 11553815. DOI: 10.1073/pnas.191367098
8. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X and Perou CM: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12: R68, 2010. PMID: 20813035 PMCID: PMC3096954 DOI: 10.1186/bcr2635
9. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan PH, Tse GM, Weigelt B, Ellis IO, Reis-Filho JS. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 24: 157-67: 2011. PMID: 21076464 DOI: 10.1038/modpathol.2010.200
10. Visvader JE and Lindeman GJ: Cancer Stem Cells: Current Status and Evolving Complexities. Cell Stem Cell 10: 717–728, 2012. PMID: 22704512. DOI: 10.1016/j.stem.2012.05.007
11. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105–111, 2001. PMID: 11689955. DOI: 10.1038/35102167
12. Nguyen NP, Almeida FS, Chi A, Nguyen LM, Cohen D, Karlsson U, Vinh-Hung V. Molecular biology of breast cancer stem cells: potential clinical applications. Cancer Treat Rev. 36: 485-91, 2010. PMID: 20231058 DOI: 10.1016/j.ctrv.2010.02.016
13. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N: The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Dicov 2: 401-404, 2012. PMID: 22588877. DOI: 10.1158/2159- 8290.CD-12-0095
14. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C and Schultz N: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: p11, 2013. PMID: 23550210. DOI: 10.1126/scisignal.2004088
15. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumors. Nature 490: 61-70, 2012. PMID: 23000897. DOI: 10.1038/nature11412
16. Rhodes DI, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandeyb A and Chinnaiyan AM: ONCOMINE: A cancer microarray database and integrated data- mining platform. Neoplasia 6: 1-6, 2004. PMID: 15068665. DOI: 10.1016/s1476-5586(04)80047-2
17. Warburg O, Wind F and Negelein E. The metabolism of tumors in the body. J Gen Physiol 8: 519-530, 1927. PMID: 19872213 DOI: 10.1085/jgp.8.6.519
18. Tamori S, Nozaki Y, Motomura H, Nakane H, Katayama R, Onaga C, Kikuchi E, Shimada N, Suzuki Y, Noike M, Hara Y, Sato K, Sato T, Yamamoto K, Hanawa T, Imai M, Abe R, Yoshimori A, Takasawa R, Tanuma S and Akimoto K: Glyoxalase 1 gene is highly expressed in basal-like human breast cancers and contributes to survival of ALDH1- positive breast cancer stem cells. Oncotarget 9: 36515-36529, 2018. PMID: 30559934. DOI: 10.18632/oncotarget.26369
19. Sakamoto H, Mashima T, Sato S, Hashimoto Y, Yamori T and Tsuruo T: Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Clin Cancer Res 7: 2513-2518, 2001. PMID: 11489834
20. Cheng WL, Tsai MM, Tsai CY, Huang YH, Chen CY, Chi HC, Tseng YH, Chao IW, Lin WC and Wu SM: Glyoxalase-I is a novel prognosis factor associated with gastric cancer progression. PLoS One 7: e34352, 2012. PMID: 22479608 DOI: 10.1371/journal.pone.0034352
21. Ranganathan S and Tew KD: Analysis of glyoxalase-I from normal and tumor tissue from human colon. Biochim Biophys Acta 1182: 311-316, 1993. PMID: 8399366 DOI: 10.1016/0925-4439(93)90074-b
22. Baunacke M, Horn LC, Trettner S, Engel KM, Hemdan NY, Wiechmann V, Stolzenburg JU, Bigl M and Bir kenmeier G: Exploring glyoxalase 1 expression in prostate cancer tissues: Targeting the enzyme by ethyl pyruvate defangs some malignancy-associated properties. Prostate 74: 48-60, 2014. PMID: 24105621 DOI: 10.1002/pros.22728
23. Bair WB III, Cabello CM, Uchida K, Bause AS and Wondrak GT: GLO1 overexpression in human malignant melanoma. Melanoma Res 20: 85-96, 2010. PMID: 20093988 DOI: 10.1097/CMR.0b013e3283364903
24. Rulli A, Carli L, Romani R, Baroni T, Giovannini E, Rosi G and Talesa V: Expression of glyoxalase I and II in normal and breast cancer tissues. Breast Cancer Res Treat 66: 67-72, 2001. PMID: 11368412 DOI: 10.1023/a:1010632919129
25. Peng HT, Chen J, Liu TY, Wu YQ, Lin XH, Lai YH and Huang YF: Up-regulation of the tumor promoter Glyoxalase-1 indicates poor prognosis in breast cancer. Int J Clin Exp Pathol 10: 10852-10862, 2017. PMID: 31966428
26. Kang Y, Edwards LG and Thornalley PJ: Effect of methylglyoxal on human leukaemia 60 cell growth: Modification of DNA G1 growth arrest and induction of apoptosis. Leuk Res 20: 97-405, 1996. PMID: 8683979 DOI: 10.1016/0145-2126(95)00162-x
27. Takasawa R, Shimada N, Uchiro H, Takahashi S, Yoshimori A, Tanuma S. TLSC702, a Novel Inhibitor of Human Glyoxalase I, Induces Apoptosis in Tumor Cells. Biol Pharm Bull. 39: 869-73. 2016. PMID: 27150153 DOI: 10.1248/bpb.b15-00710
28. Zhang D, Tai LK, Wong LL, Chiu LL, Sethi SK and Koay ES: Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER- 2/neu-positive breast cancer. Mol Cell Proteomics 4: 1686-1696, 2005. PMID: 16048908 DOI: 10.1074/mcp.M400221-MCP200
29. Gandalovičová A, Vomastek T, Rosel D and Brábek J: Cell polarity signaling in the plasticity of cancer cell invasiveness. Oncotarget 7: 250221 25049, 2016. PMID: 26872368 DOI: 10.18632/oncotarget.7214
30. Akimoto K, Mizuno K, Osada S, Hirai S, Tanuma S, Suzuki K and Ohno S: A new member of the third class in the protein kinase C family, PKC lambda, expressed dominantly in an undifferentiated mouse embryonal carcinoma cell line and also in many tissues and cells. J Biol Chem 269: 12677-12683, 1994. PMID: 7513693.
31. Suzuki A, Akimoto K and Ohno S: Protein kinase C lambda/iota (PKClambda/iota): a PKC isotype essential for the development of multicellular organisms. J Biochem 133: 9-16, 2003. PMID: 12761193. DOI: 10.1093/jb/mvg018
32. Nozaki Y, Motomura H, Tamori S, Kimura Y, Onaga C, Kanai S, Ishihara Y, Ozaki A, Hara Y, Harada Y, Mano Y, Sato T, Sato K, Sasaki K, Ishiguro H, Ohno S and Akimoto K: High PKCλ expression is required for ALDH1-positive cancer stem cell function and indicates a poor clinical outcome in late-stage breast cancer patients. PLoS One 15: e0235747, 2020. PMID: 32658903 DOI: 10.1371/journal.pone.0235747
33. Parker PJ, Justilien V, Riou P, Linch M and Fields AP: Atypical protein kinase Cι as a human oncogene and therapeutic target. Biochem Pharmacol 88: 1-11, 2014. PMID: 24231509. DOI: 10.1016/j.bcp.2013.10.023
34. Kojima Y, Akimoto K, Nagashima Y, Ishiguro H, Shirai S, Chishima T, Ichikawa Y, Ishikawa T, Sasaki T, Kubota Y, Inayama Y, Aoki I, Ohno S and Shimada H: The overexpression and altered localization of the atypical protein kinase C lambda/iota in breast cancer correlates with the pathologic type of these tumors. Hum Pathol 39: 824-31, 2008. PMID: 18538170. DOI: 10.1016/j.humpath.2007.11.001
35. Paul A, Gunewardena S, Stecklein SR, Saha B, Parelkar N, Danley M, Rajendran G, Home P, Ray S, Jokar I, Vielhauer GA, Jensen RA, Tawfik O and Paul S: PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis. Cell Death Differ 21: 1469- 1481, 2014. PMID: 24786829. DOI: 10.1038/cdd.2014.62
36. Mizushima T, Asai-Sato M, Akimoto K, Nagashima Y, Taguri M, Sasaki K, Nakaya MA, Asano R, Tokinaga A, Kiyono T, Hirahara F, Ohno S and Miyagi E: Aberrant Expression of the Cell Polarity Regulator aPKCλ/ι is Associated With Disease Progression in Cervical Intraepithelial Neoplasia (CIN): A Possible Marker for Predicting CIN Prognosis. Int J Gynecol Pathol 35: 106-117, 2016. PMID: 26535980. DOI: 10.1097/PGP.0000000000000228
37. Tokinaga-Uchiyama A, Mizushima T, Akimoto K, Nagashima Y, Sasaki K, Nakaya MA, Ohashi K, Kubota K, Maruyama Y, Kato H, Hirahara F, Miyagi E, Ohno S and Asai-Sato M: Aberrant nuclear localization of aPKCλ/ι is associated with poorer prognosis in uterine cervical cancer. Int J Gynecol Pathol 38: 301-309, 2019. PMID: 30059452. DOI: 10.1097/PGP.0000000000000539
38. Baba J, Kioi M, Akimoto K, Nagashima Y, Taguri M, Inayama Y, Aoki I, Ohno S, Mitsudo K and Tohnai I: Atypical Protein Kinase Cλ/ι Expression Is Associated with Malignancy of Oral Squamous Cell Carcinoma. Anticancer Res 38: 6291-6297, 2018. PMID: 30396949. DOI: 10.21873/anticanres.12985
39. Ishiguro H, Akimoto K, Nagashima Y, Kagawa E, Sasaki T, Sano JY, Takagawa R, Fujinami K, Sasaki K, Aoki I, Ohno S, Kubota Y and Uemura H: Coexpression of aPKCλ/ι and IL-6 in prostate cancer tissue correlates with biochemical recurrence. Cancer Sci 102: 1576-1581, 2011. PMID: 21535317. DOI: 10.1111/j.1349-7006.2011.01972.x
40. Ishiguro H, Akimoto K, Nagashima Y, Kojima Y, Sasaki T, Ishiguro-Imagawa Y, Nakaigawa N, Ohno S, Kubota Y and Uemura H: aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proc Natl Acad Sci U S A 106: 16369-16374, 2009. PMID: 19805306. DOI: 10.1073/pnas.0907044106
41. Regala RP, Weems C, Jamieson L, Khoor A, Edell ES, Lohse CM and Fields AP: Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res 65: 8905-8911, 2005. PMID: 16204062. DOI: 10.1158/0008-5472.CAN-05-2372
42. Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP, Kango-Singh M, Lu KH, Warneke CL, Atkinson EN, Bedrosian I, Keyomarsi K, Kuo WL, Gray JW, Yin JC, Liu J, Halder G and Mills GB: Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A 102: 12519-12524, 2005. PMID: 16116079. DOI: 10.1073/pnas.0505641102
43. Kato S, Akimoto K, Nagashima Y, Ishiguro H, Kubota K, Kobayashi N, Hosono K, Watanabe S, Sekino Y, Sato T, Sasaki K, Nakaigawa N, Kubota Y, Inayama Y, Endo I, Ohno S, Maeda S and Nakajima A: aPKCλ/ι is a beneficial prognostic marker for pancreatic neoplasms. Pancreatology 13: 360-368, 2013. PMID: 23890134. DOI: 10.1016/j.pan.2013.05.006
44. Takagawa R, Akimoto K, Ichikawa Y, Akiyama H, Kojima Y, Ishiguro H, Inayama Y, Aoki I, Kunisaki C, Endo I, Nagashima Y and Ohno S. High expression of atypical protein kinase C lambda/iota in gastric cancer as a prognostic factor for recurrence. Ann Surg Oncol 17: 81-88, 2010. PMID: 19774416. DOI: 10.1245/s10434-009-0708-x
45. Motomura H, Nozaki Y, Onaga C, Ozaki A, Tamori S, Shiina TA, Kanai S, Ohira C, Hara Y, Harada Y, Takasawa R, Hanawa T, Tanuma SI, Mano Y, Sato T, Sato K and Akimoto K: High expression of c-Met, PKCλ and ALDH1A3 predicts a poor prognosis in late-stage breast cancer. Anticancer Res 40: 35-52, 2020. PMID: 31892551 DOI: 10.21873/anticanres.13924
46. Reina-Campos M, Diaz-Meco MT, Moscat J. The Dual Roles of the Atypical Protein Kinase Cs in Cancer. Cancer Cell 36: 218-235, 2019. PMID: 31474570 PMCID: PMC6751000 DOI: 10.1016/j.ccell.2019.07.010
47. Sasaki K, Kojitani N, Hirose H, Yoshihama Y, Suzuki H, Shimada M, Takayanagi A, Yamashita A, Nakaya MA, Hirano H, Takahashi H, Ohno S. Shank2 Binds to aPKC and Controls Tight Junction Formation with Rap1 Signaling during Establishment of Epithelial Cell Polarity. Cell Rep. 31: 107407, 2020. PMID: 32268103 DOI: 10.1016/j.celrep.2020.02.088
48. Varghese F, Bukhari AB, Malhotra R, De A: IHC Profiler: An Open Source Plugin for the Quantitative Evaluation and Automated Scoring of Immunohistochemistry Images of Human Tissue Samples. PLoS One 9: e96801, 2014. PMID: 24802416 DOI: 10.1371/journal.pone.0096801
49. Stallings-Mann M, Jamieson L, Regala RP, Weems C, Murray NR and Fields AP: A novel small‑molecule inhibitor of protein kinase Ciota blocks transformed growth of non‑small‑cell lung cancer cells. Cancer Res 66: 1767-1774, 2006. PMID: 16452237 DOI: 10.1158/0008-5472.CAN-05-3405
50. Trani M, Sorrentino A, Busch C and Landström M: Pro-apoptotic effect of aurothiomalate in prostate cancer cells. Cell Cycle 8: 306-313, 2009. PMID: 19164922 DOI: 10.4161/cc.8.2.7596
51. Chiavarina B, Nokin M-J, Durieux F, Bianchi E, Turtoi A, Peulen O, Peixoto P, Irigaray P, Uchida K, Belpomme D, Delvenne P, Castronovo V, Bellahcène A: Triple negative tumors accumulate significantlyvless methylglyoxal specific adducts than other human breast cancer subtypes. Oncotarget 5: 5472-5482, 2014. PMID: 24978626 DOI: 10.18632/oncotarget.2121
52. Justilien V and Fields AP: Ect2 links the PKCiota-Par6alpha complex to Rac1 activation and cellular transformation. Oncogene 28: 3597-3607, 2009. PMID: 19617897. DOI: 10.1038/onc.2009.217
53. Regala RP, Weems C, Jamieson L, Copland JA, Thompson EA, Fields AP: Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J Biol Chem. 280: 31109-31115, 2005. PMID: 15994303 DOI: 10.1074/jbc.M505402200
54. Riddell M, Nakayama A, Hikita T, Mirzapourshafiyi F, Kawamura T, Pasha A: aPKC controls endothelial growth by modulating c-Myc via FoxO1 DNA-binding ability. Nat Commun. 9: 5357, 2018. PMID: 30559384 PMCID: PMC6297234 DOI: 10.1038/s41467-018-07739-0
55. Guo Y, Zhang Y, Yang X, Lu P, Yan X, Xiao F, Zhou H, Wen C, Shi M, Lu J, Meng QH. Effects of methylglyoxal and glyoxalase I inhibition on breast cancer cells proliferation, invasion, and apoptosis through modulation of MAPKs, MMP9, and Bcl-2. Cancer Biol Ther. 17: 169–180, 2016. PMID: 26618552 DOI: 10.1080/15384047.2015.1121346
56. Singh S, Brocker C, Koppaka V, Chen Y, Jackson BC, Matsumoto A: Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress. Free Radic Biol Med. 56: 89-101, 2013. PMID: 23195683 DOI: 10.1016/j.freeradbiomed.2012.11.010
57. Szablewski L. Expression of glucose transporters in cancers. Biochim Biophys Acta 1835: 164-169, 2013. PMID: 23266512 DOI: 10.1016/j.bbcan.2012.12.004
58. Hussein YR, Bandyopadhyay S, Semaan A, Ahmed Q, Albashiti B, Jazaerly T, Nahleh Z, Ali-Fehmi R. Glut-1 Expression Correlates with Basal-like Breast Cancer. Transl Oncol 4: 321-327, 2011. PMID: 22190995 PMCID: PMC3243654 DOI: 10.1593/tlo.11256
59. Bosch RR, Bazuine M, Span PN, Willems PH, Olthaar AJ, van Rennes H, Maassen JA, Tack CJ, Hermus AR and Sweep CG: Regulation of GLUT1-mediated glucose uptake by PKClambda-PKCbeta(II) interactions in 3T3-L1 adipocytes. Biochem J 384: 349-355, 2004. PMID: 15307820 PMCID: PMC1134118 DOI: 10.1042/BJ20040797
60. Liu L, Lei B, Wang L, Chang C, Yang H, Liu J, Huang G and Xie W: Protein kinase C- iota-mediated glycolysis promotes non-small-cell lung cancer progression. Onco Targets Ther 12: 5835-5848, 2019. PMID: 31410027 PMCID: PMC6646854 DOI: 10.2147/OTT.S207211
61. Kotani K, Ogawa W, Matsumoto M, T Kitamura, Sakaue H, Hino Y, Miyake K, Sano W, Akimoto K, Ohno S, Kasuga M. Requirement of atypical protein kinase clambda for insulin stimulation of glucose uptake but not for Akt activation in 3T3-L1 adipocytes. Mol Cell Biol 18: 6971-6982, 1998. PMID: 9819385 PMCID: PMC109280 DOI: 10.1128/MCB.18.12.6971
62. R.V. Farese. Function and dysfunction of aPKC isoforms for glucose transport in insulin- sensitive and insulin-resistant states. Am J Physiol Endocrinol Metab. 283: E1-11, 2002. PMID: 12067836 DOI: 10.1152/ajpendo.00045.2002
63. Tisdale EJ: Glyceraldehyde-3-phosphate dehydrogenase is phosphorylated by protein kinase Ciota /lambda and plays a role in microtubule dynamics in the early secretory pathway. J Biol Chem 277: 3334-3341, 2002. PMID: 11724794 DOI: 10.1074/jbc.M109744200
64. Tisdale EJ: Rab2 interacts directly with atypical protein kinase C (aPKC) iota/lambda and inhibits aPKCiota/lambda-dependent glyceraldehyde-3-phosphate dehydrogenase phosphorylation. J Biol Chem 278: 52524-52530, 2003. PMID: 14570876 DOI: 10.1074/jbc.M309343200
65. Kim JY, Valencia T, Abu-Baker S, Linares J, Lee SJ, Yajima T, Chen J, Eroshkin A, Castilla EA, Brill LM, Medvedovic M, Leitges M, Moscat J, Diaz-Meco MT: c-Myc phosphorylation by PKCζ represses prostate tumorigenesis. Proc Natl Acad Sci USA 110: 6418-6423, 2013. PMID: 23550155 DOI: 10.1073/pnas.1221799110
66. Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, Xu Y, Wonsey D, Lee LA, Dang CV: Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 275: 21797-21800, 2000. PMID: 10823814 DOI: 10.1074/jbc.C000023200
67. Gjyshi O, Bottero V, Veettil MV, Dutta S, Singh VV, Chikoti L: Kaposi’s sarcoma- associated herpesvirus induces Nrf2 during de novo infection of endothelial cells to create a microenvironment conducive to infection. PLoS Pathog. 10: e1004460, 2014. PMID: 25340789 DOI: 10.1371/journal.ppat.1004460
68. Ma L, Tao Y, Duran A, Llado V, Galvez A, Barger JF, Castilla EA, Chen J, Yajima T, Porollo A, Medvedovic M, Brill LM, Plas DR, Riedl SJ, Leitges M, Diaz-Meco MT, Richardson AD, Moscat J: Control of nutrient stress-induced metabolic reprogramming by PKCζ in tumorigenesis. Cell 152: 599-611, 2013. PMID: 23374352 DOI: 10.1016/j.cell.2012.12.028
69. Franchet C, Duprez-Paumier R, Lacroix-Triki M: Molecular taxonomy of luminal breast cancer in 2015. Bull Cancer 102: S34-46, 2015. PMID: 26118875 DOI: 10.1016/S0007-4551(15)31216-9
70. Liu Z, Zhang XS, Zhang S: Breast tumor subgroups reveal diverse clinical prognostic power. Sci Rep 4: 4002, 2014. PMID: 24499868 DOI: 10.1038/srep04002
71. Ricardo S, Vieira AF, Gerhard R, Leitão D, Pinto R, Cameselle-Teijeiro JF and, Milanezi F, Schmitt F and Paredes J: Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 64: 937–946, 2011. PMID: 21680574. DOI: 10.1136/jcp.2011.09045
72. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS and Dontu G: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1: 555–567, 2007. PMID: 18371393. DOI: 10.1016/j.stem.2007.08.014
73. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA and Katz RL: Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 7: 330–338, 2009. PMID: 19276181. DOI: 10.1158/1541- 7786.MCR-08-0393
74. Su Y, Qiu Q, Zhang X, Jiang Z, Leng Q, Liu Z, Stass SA and Jiang F: ALDH1A1 Positive Cell Population Is Enriched in Tumor-initiating Cells and Associated with Progression of Bladder Cancer. Cancer Epidemiol Biomarkers Prev 19: 327-337, 2010. PMID: 20142235. DOI: 10.1158/1055-9965.EPI-09-0865
75. Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC Jr, Coleman RL, Lopez-Berestein G and Sood AK: Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Molecular Cancer Therapeutics 9: 3186-3199, 2010. PMID: 20889728. DOI: 10.1158/1535- 7163.MCT-10-0563
76. Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB and Gallick GE: ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One 6: e20636, 2011. PMID: 21695188. DOI: 10.1371/journal.pone.0020636
77. Marcato P, Dean CA, Liu RZ, Coyle KM, Bydoun M, Wallace M, Clements D, Turner C, Mathenge EG, Gujar SA, Giacomantonio CA, Mackey JR, Godbout R and Lee PW: Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling. Mol Oncol 9: 17-31, 2015. PMID: 25106087. DOI: 10.1016/j.molonc.2014.07.010
78. Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer L, Pan L, Leidal A, Gujar S, Giacomantonio CA and Lee PW: Aldehyde Dehydrogenase Activity of Breast Cancer Stem Cells is Primarily Due to Isoform ALDH1A3 and Its Expression is Predictive of Metastasis. Stem Cells 29: 32-45, 2011. PMID: 21280157. DOI: 10.1002/stem.563
79. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 101: 736-50, 2009. PMID: 19436038 PMCID: PMC2684553 DOI: 10.1093/jnci/djp082
80. Figueroa-Magalhães MC, Jelovac D, Connolly R, Wolff AC. Treatment of HER2-positive breast cancer. Breast. 23: 128-136, 2014. PMID: 24360619 PMCID: PMC4466908 DOI: 10.1016/j.breast.2013.11.011
81. Nozaki Y, Tamori S, Inada M, Katayama R, Nakane H, Minamishima O, Onodera Y, Abe M, Shiina S, Tamura K, Kodama D, Sato K, Hara Y, Abe R, Takasawa R, Yoshimori A, Shinomiya N, Tanuma SI and Akimoto K: Correlation between c-Met and ALDH1 contributes to the survival and tumor-sphere formation of ALDH1 positive breast cancer stem cells and predicts poor clinical outcome in breast cancer. Genes Cancer 8: 628-639, 2017. PMID: 28966724. DOI: 10.18632/genesandcancer.148
82. Wang Y, Hill KS and Fields AP: PKCι maintains a tumor-initiating cell phenotype that is required for ovarian tumorigenesis. Mol Cancer Res 11: 1624-1635, 2013. PMID: 24174471. DOI: 10.1158/1541-7786.MCR-13-0371-T
83. Erdogan E, Lamark T, Stallings-Mann M, Lee Jamieson, Pellecchia M, Thompson EA, Johansen T, Fields AP. Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Cι. J Biol Chem 281: 28450-9, 2006. PMID: 16861740 DOI: 10.1074/jbc.M606054200
84. Butler AM, Scotti Buzhardt ML, Erdogan E, Li S, Inman KS, Fields AP, Murray NR. A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion. Oncotarget 6: 15297-310, 2015. PMID: 25915428 PMCID: PMC4558152 DOI: 10.18632/oncotarget.3812
85. Li H, Hu J, Wu S, Wang L, Cao X, Zhang X, Dai B, Cao M, Shao R, Zhang R, Majidi M, Ji L, Heymach JV, Wang M, Pan S, Minna J, Mehran RJ, Swisher SG, Roth JA, Fang B. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non- small cell lung cancer cells. Oncotarget; 7: 3548-58, 2016. PMID: 26657290 PMCID: PMC4823126 DOI: 10.18632/oncotarget.6516
86. Kobayashi H, Takeno M, Saito T, Takeda Y, Kirino Y, Noyori K, Hayashi T, Ueda A, Ishigatsubo Y. Regulatory role of heme oxygenase 1 in inflammation of rheumatoid arthritis. Arthritis Rheum 54: 1132-42, 2006. PMID: 16572448 DOI: 10.1002/art.21754
87. Li H, Ma F, Wang H, Lin C, Fan Y, Zhang X, Qian H and Xu B: Stem cell marker aldehyde dehydrogenase 1 (ALDH1)-expressing cells are enriched in triple-negative breast cancer. Int J Biol Markers 28: e357-64, 2013. PMID: 24338721. DOI: 10.5301/jbm.5000048
88. Lønning PE, Sørlie T and Børresen-Dale AL: Genomics in breast cancer-therapeutic implications. Nat Clin Pract Oncol 2: 2633, 2005. PMID: 16264853. DOI: 10.1038/ncponc0072
89. Maughan KL, Lutterbie MA and Ham PS: Treatment of breast cancer: Am Fam Physician 81: 1339-1346, 2010. PMID: 20521754
90. Korkaya H, Paulson A, Iovino F and Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27: 6120- 30: 2008. PMID: 18591932 DOI: 10.1038/onc.2008.207
91. Korkaya H and Wicha MS. HER2 and breast cancer stem cells: more than meets the eye. Cancer Res 73: 3489-93: 2013. PMID: 23740771 DOI: 10.1158/0008-5472.CAN-13-0260
92. Izaguirre G, Kikonyogo A and Pietruszko R: Methylglyoxal as substrate and inhibitor of human aldehyde dehydrogenase: Comparison of kinetic properties among the three isozymes. Comp Biochem Physiol B Biochem Mol Biol. 119: 747–754: 1998. PMID: 9787766 DOI: 10.1016/s0305-0491(98)00051-0
93. Takeuchi M, Kimura S, Kuroda J, Ashihara E, Kawatani M, Osada H, Umezawa K, Yasui E, Imoto M, Tsuruo T, Yokota A, Tanaka R and Nagao R: Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment. Cell Death Differ 17: 1211-1220: 2010. PMID: 20139893 DOI: 10.1038/cdd.2010.6
94. Zang G, Mu Y, Gao L, Bergh A, Landström M: PKCζ facilitates lymphatic metastatic spread of prostate cancer cells in a mice xenograft model. Oncogene. 38: 4215–4231, 2019. PMID: 30705401 PMCID: PMC6756056 DOI: 10.1038/s41388-019-0722-9
95. Justilien V, Walsh MP, Ali SA, Thompson EA, Murray NR and Fields AP: The PRKCI and SOX2 Oncogenes are Co-amplified and Cooperate to Activate Hedgehog Signaling in Lung Squamous Cell Carcinoma. Cancer Cell 25: 139-151, 2014. PMID: 24525231. DOI: 10.1016/j.ccr.2014.01.008
96. Ali SA, Justilien V, Jamieson L, Murray NR and Fields AP: Protein Kinase Cι drives a NOTCH3-dependent stem-like phenotype in mutant KRAS lung adenocarcinoma. Cancer Cell 29: 367-378, 2016. PMID: 26977885. DOI: 10.1016/j.ccell.2016.02.012
97. Phillips E, Lang V, Bohlen J, Bethke F, Puccio L, Tichy D, Herold-Mende C, Hielscher T, Lichter P and Goidts V: Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism. Int J Cancer 139: 1776- 1787, 2016. PMID: 27299852. DOI: 10.1002/ijc.30234
98. Sammut SJ, Crispin-Ortuzar M, Chin SF, Provenzano E, Bardwell HA, Ma W, Cope W, Dariush A, Dawson SJ, Abraham JE, Dunn J, Hiller L, Thomas J, Cameron DA, Bartlett JMS, Hayward L, Pharoah PD, Markowetz F, Rueda OM, Earl HM, Caldas C: Multi-omic machine learning predictor of breast cancer therapy response. Nature. Online ahead of print, 2021. PMID: 34875674. DOI: 10.1038/s41586-021-04278-5
99. Sato K and Akimoto K: Expression levels of KMT2C and SLC20A1 identified by information-theoretical analysis are powerful prognostic biomarkers in estrogen receptor- positive breast cancer. Clin Breast Cancer 17: e135-e142, 2017. PMID: 27986439. DOI:10.1016/j.clbc.2016.11.005
100. Sato K, Tahata K, Akimoto K: Five genes associated with survival in patients with lower- grade gliomas were identified by information-theoretical analysis. Anticancer Res. 40:2777-2785, 2020. PMID: 32366424 DOI: 10.21873/anticanres.14250